Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trialMehreen S. Datoo, Halidou Tinto, Karim Derra et al.|The Lancet|2021Cited by 457
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S. Datoo, Nsajigwa Misidai, Alassane Dicko et al.|The Lancet|2024Cited by 345
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trialMehreen S. Datoo, Halidou Tinto, Hamtandi Magloire Natama et al.|The Lancet Infectious Diseases|2022Cited by 285
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling studyNora Schmit, Peter Winskill, Hillary M. Topazian et al.|The Lancet Infectious Diseases|2024Cited by 48
A Phase III Randomised Controlled Trial Evaluating the Malaria Vaccine Candidate R21/Matrix-M™ in African ChildrenMehreen Datoo, Adrian V. S. Hill, Alassane Dicko et al.|SSRN Electronic Journal|2023Cited by 29